Diabetes and Metabolic Disorders: The Approval of Teplizumab
Teplizumab, the first disease-modifying therapy for Type 1 diabetes, delays disease onset by ~4 years in high-risk individuals. Priced at $194,000 per course, it redefines early intervention despite cost barriers.
June 23, 2025
by David Orchard-Webb
FDA Approves Automated Insulin Delivery, Monitoring System for Young Pediatric Patients
The U.S. Food and Drug Administration (FDA) approved the MiniMed 770G System, a hybrid closed loop diabetes management device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses with little or no input ...
September 2, 2020
by americanpharmaceuticalreview
Artificial pancreas for type 1 diabetes control given nod by FDA
The all-in-one, Control-IQ system controlled the blood glucose levels of children aged six and over more successfully than standard technologies in a clinical trials.
August 28, 2020
by europeanpharmaceuticalreview
Research links COVID-19 to rise in childhood type 1 diabetes
This study analysed data from 30 children in London hospitals diagnosed with new-onset type 1 diabetes during the first peak of the pandemic.
August 24, 2020
by expresspharma
Provention Bio Initiates Rolling Submission of BLA for Teplizumab for Type 1 Diabetes
Provention Bio announced the initiation of the rolling submission of the Company's Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for teplizumab (PRV-031).
April 17, 2020
by americanpharmaceuticalreview
FDA hands Boehringer and Lilly complete response letter for insulin adjunct
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
March 26, 2020
Boehringer, Lilly Get Complete Response Letter for Empagliflozin
FDA is unable to approve sNDA for Empagliflozin in type 1 diabetes.
March 24, 2020
by contractpharma
Provention Bio Provides Pauses Type 1 Diabetes Treatment Study
Provention Bio announced a temporary pause in the randomization of patients with newly diagnosed type 1 diabetes (T1D) into its global Phase 3 PROTECT study of PRV-031 (teplizumab).
March 20, 2020
by americanpharmaceuticalreview
Severe Hypoglycemia in Seniors With T1DM May Worsen Cognition
Both recent severe hypoglycemia (SH) and lifetime SH are associated with worse cognition among older adults with type 1 diabetes, according to a study published online December in Diabetes Care.
January 6, 2020
by drugs
Big Advances Made Against Diabetes in 2019
A new artificial pancreas system, drugs that help control blood sugar and protect the heart and the kidneys, a new medication that delays type 1 diabetes ...
January 2, 2020
by drugs
High Lipoprotein(a) Is Risk Factor for CVD in Type 1 Diabetes
For patients with type 1 diabetes, lipoprotein(a) [Lp(a)] is a significant risk factor for macrovascular disease, albuminuria, and calcified aortic valve disease ...
December 31, 2019
by drugs
FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes
The setback comes as Sanofi works to revive declining sales from its diabetes division and faces increasing pressure from politicians and patient advocacy groups over the rising cost of its insulin products.
March 26, 2019
by expressbpd